Nivolumab Drug Donation Policy 2023

Nivolumab (Nivolumab) is a type of cancer treatment called immunotherapy, a treatment for many different types of cancer, also known as Opdivo. Doctors may give nivolumab alone or in combination with other cancer drugs, depending on the type of cancer a patient has. Patients may also receive nivolumab as part of a clinical trial.

The drug donation policy of nivolumab may require patients to learn about it through relevant institutions, and its price will be reduced, thereby reducing the burden on patients and increasing the progress of drug treatment. Drug donation policies generally focus on patients who have a heavy financial burden or do not have adequate medical reimbursement conditions; if doctors from local hospitals can submit an application for drug donation, they can obtain approval for drug donation by providing patient medical records and other diagnostic information. Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). It was developed by Bristol Myers Squibb and will be provided to patients if their drug donation application is approved.

The generic drug Nivolumab is currently on the market in China, but it has not yet been included in medical insurance. This drug is a strictly controlled drug, and its purchase channels are restricted. Specifications The price of each box of 40mg/4ml may be around RMB 4,000. The Turkish version of the nivolumab generic drug listed overseas may cost more than RMB 2,000 per box of 40mg/4ml (the price may fluctuate due to exchange rates). Currently, there is no generic version of nivolumab available on the market. For more drug information and specific prices, please consult a medical consultant.